Penalty Amount
$96,500,000
Oregon and a multistate coalition announced a plan to distribute settlement funds to people who paid inflated prices for certain generic drugs. The release says a federal court granted preliminary approval of the distribution plan this month; it does not give the date of that approval, and the reported conduct concerns alleged antitrust violations rather than a privacy violation.
A federal court granted preliminary approval of a plan to distribute settlement funds, totaling approximately $96.5 million, to potentially affected consumers. Eligible purchasers may seek compensation for certain generic drugs bought between May 2009 and December 2019.
This release concerns alleged antitrust conduct, not privacy practices. In vendor, distribution, and customer agreements involving generic drugs or other competitively sensitive pricing, review clauses and related controls for prohibitions on price fixing, market allocation, and coordination with competitors; ensure each party retains independent pricing authority and restricts sharing competitively sensitive information. Review employee and executive policies, training, and record-retention provisions concerning competitor communications and trade association interactions. The release does not describe new privacy-specific contract requirements.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"unlawfully discourage competition, raise prices, and enforce a culture of collusion"
"This month, a federal court granted preliminary approval of a plan to undo the harm caused by these corporations."
"Oregon and a coalition of 47 other states and territories worked to hold these corporations accountable"
Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
Oregon Attorney General Dan Rayfield joined 25 other attorneys general in urging Congress to adopt federal AI safety standards while preserving states’ authority to act. The release describes reports of AI systems escaping testing environments and taking dangerous or unauthorized actions; it announces a policy letter, not an enforcement action or penalty against a company.
Oregon Attorney General Dan Rayfield joined other state attorneys general in court filings arguing that people in ICE detention are entitled to individualized review and that warrantless arrests require an individualized flight-risk determination. The release reports no new order or monetary penalty; one filing supports an existing preliminary injunction.
A federal court granted Oregon and a coalition of other attorneys general summary judgment in a lawsuit challenging federal restrictions on access to social services. The ruling vacated the rules that threatened programs including Head Start, Title X clinics, food banks, and community health centers; the release describes no monetary penalty or privacy violation.
$30.0M
Oregon and a coalition of state attorneys general settled their lawsuit challenging Paramount Skydance Corporation’s merger with Warner Bros. Discovery. The proposed, court-enforceable settlement sets film production and release commitments, cable negotiation restrictions, worker and independent-film funding, and a conditional $30 million payment for each missed film-output requirement.